Brief: Allovir Inc Notifies SVB Securities That It Was Terminating Prospectus Supplement
June 21 (Reuters) - Allovir Inc ALVR.O :
* ALLOVIR INC - NOTIFIED SVB SECURITIES THAT IT WAS
SUSPENDING ITS
USE OF AND TERMINATING PROSPECTUS SUPPLEMENT
* ALLOVIR: PROSPECTUS SUPPLEMENT RELATED TO POTENTIAL
ISSUANCE
FROM TIME TO TIME OF CO'S COMMON STOCK PURSUANT TO SALES
AGREEMENT DATED AUGUST 6, 2021
Source: (https://shorturl.at/CHIJ7)
Further company coverage: ALVR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million